Cargando…

Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017

BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Imtiaz, Mach, Ondrej, Hamid, Nasir A., Bhatti, Zaid S., Moore, Deborah D., Oberste, M. Steven, Khan, Shahid, Khan, Hasan, Weldon, William C., Sutter, Roland W., Bhutta, Zulfiqar A, Soofi, Sajid B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873527/
https://www.ncbi.nlm.nih.gov/pubmed/29510918
http://dx.doi.org/10.1016/j.vaccine.2018.02.055
_version_ 1783310046244896768
author Hussain, Imtiaz
Mach, Ondrej
Hamid, Nasir A.
Bhatti, Zaid S.
Moore, Deborah D.
Oberste, M. Steven
Khan, Shahid
Khan, Hasan
Weldon, William C.
Sutter, Roland W.
Bhutta, Zulfiqar A
Soofi, Sajid B.
author_facet Hussain, Imtiaz
Mach, Ondrej
Hamid, Nasir A.
Bhatti, Zaid S.
Moore, Deborah D.
Oberste, M. Steven
Khan, Shahid
Khan, Hasan
Weldon, William C.
Sutter, Roland W.
Bhutta, Zulfiqar A
Soofi, Sajid B.
author_sort Hussain, Imtiaz
collection PubMed
description BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we collected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies. RESULTS: A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to poliovirus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and 91% for PV2; 93% and 98% for PV3. Age group (RR = 3.6, CI 95% = 2.2–5.6) and place of residence outside of Kandahar city (RR = 1.8, CI 95% = 1.2–2.6) were found to be significant risk factors for seronegativity. CONCLUSIONS: The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication.
format Online
Article
Text
id pubmed-5873527
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-58735272018-04-05 Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017 Hussain, Imtiaz Mach, Ondrej Hamid, Nasir A. Bhatti, Zaid S. Moore, Deborah D. Oberste, M. Steven Khan, Shahid Khan, Hasan Weldon, William C. Sutter, Roland W. Bhutta, Zulfiqar A Soofi, Sajid B. Vaccine Article BACKGROUND: Afghanistan is one of the remaining wild-poliovirus (WPV) endemic countries. We conducted a seroprevalence survey of anti-poliovirus antibodies in Kandahar Province. METHODS: Children in two age groups (6–11 months and 36–48 months) visiting Mirwais hospital in Kandahar for minor ailments unrelated to polio were enrolled. After obtaining informed consent, we collected venous blood and conducted neutralization assay to detect poliovirus neutralizing antibodies. RESULTS: A total of 420 children were enrolled and 409/420 (97%) were analysed. Seroprevalence to poliovirus type 1 (PV1) was 97% and 100% in the younger and older age groups respectively; it was 71% and 91% for PV2; 93% and 98% for PV3. Age group (RR = 3.6, CI 95% = 2.2–5.6) and place of residence outside of Kandahar city (RR = 1.8, CI 95% = 1.2–2.6) were found to be significant risk factors for seronegativity. CONCLUSIONS: The polio eradication program in Kandahar achieved high serological protection, especially against PV1 and PV3. Lower PV2 seroprevalence in the younger age group is a result of a withdrawal of live type 2 vaccine in 2016 and is expected. Ability to reach all children with poliovirus vaccines is a pre-requisite for achieving poliovirus eradication. Elsevier Science 2018-04-05 /pmc/articles/PMC5873527/ /pubmed/29510918 http://dx.doi.org/10.1016/j.vaccine.2018.02.055 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Hussain, Imtiaz
Mach, Ondrej
Hamid, Nasir A.
Bhatti, Zaid S.
Moore, Deborah D.
Oberste, M. Steven
Khan, Shahid
Khan, Hasan
Weldon, William C.
Sutter, Roland W.
Bhutta, Zulfiqar A
Soofi, Sajid B.
Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title_full Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title_fullStr Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title_full_unstemmed Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title_short Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017
title_sort seroprevalence of anti-polio antibodies in children from polio high risk area of afghanistan: a cross sectional survey 2017
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873527/
https://www.ncbi.nlm.nih.gov/pubmed/29510918
http://dx.doi.org/10.1016/j.vaccine.2018.02.055
work_keys_str_mv AT hussainimtiaz seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT machondrej seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT hamidnasira seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT bhattizaids seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT mooredeborahd seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT oberstemsteven seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT khanshahid seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT khanhasan seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT weldonwilliamc seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT sutterrolandw seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT bhuttazulfiqara seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017
AT soofisajidb seroprevalenceofantipolioantibodiesinchildrenfrompoliohighriskareaofafghanistanacrosssectionalsurvey2017